Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ultomiris (ravulizumab-cwvz)
Pharma
AZ leans on cancer, rare disease muscle in solid Q2
In 2026’s second quarter, AstraZeneca generated revenue of nearly $15.4 million, growing 5% over the same period in 2025 at constant currencies.
Fraiser Kansteiner
Jul 27, 2026 10:21am
AZ's Ultomiris hits goal in ph. 3 IgAN trial
Apr 21, 2026 10:35am
Amgen nabs FDA nod for Uplizna in generalized myasthenia gravis
Dec 12, 2025 9:49am
Novartis sues AZ's Alexion over 'misleading' Ultomiris marketing
Oct 22, 2025 1:19pm
AZ touts Ultomiris results in post-transplant complication trial
Jun 16, 2025 10:32am
AZ’s Alexion creates interactive storybook for kids with aHUS
Feb 12, 2025 12:00pm
